Your only mesothelioma treatments news source!
Click on each item to read full story.

 
Mesothelioma Cancer Research Foundation Broadcasting Symposium Live
read story
The Mesothelioma Applied Research Foundation (Meso Foundation) will broadcast live, free of charge, its Symposium sessions on Tuesday, March 3, starting at 9:30 AM Eastern Time. (PRWeb February 28, 2015) Read the full story at http://www.prweb.com/releases/2015/03/prweb12551849.htm
 
Research Study Highlights Promising New Mesothelioma Therapies, According to Surviving Mesothelioma
read story
One of the country’s top mesothelioma researchers has published a new summary of some of the most promising emerging therapies for the deadly cancer. (PRWeb February 25, 2015) Read the full story at http://www.prweb.com/releases/2015/02/prweb12536377.htm
 
Conference on Mesothelioma Co-Hosted with National Cancer Institute
read story
On March 2-4, the Mesothelioma Applied Research Foundation and the National Cancer Institute (NCI) will co-host the annual International Symposium on Malignant Mesothelioma at the National Institutes of Health (NIH). (PRWeb February 27, 2015) Read the full story at http://www.prweb.com/releases/2015/03/prweb12551221.htm
 
Cancer Research Foundation Honors Award Recipients
read story
The Mesothelioma Applied Research Foundation will honor its awards recipients during its annual Awards Dinner, on Monday, March 2 for their hard work in the mission to cure mesothelioma. (PRWeb February 28, 2015) Read the full story at http://www.prweb.com/releases/2015/03/prweb12551495.htm
 
Novocure Enrolls the First Patient in its Phase II STELLAR Trial of Tumor Treating Fields Together with Pemetrexed and ...
read story
Novocure, a commercial stage oncology company, announced today that the first patient has been enrolled in the STELLAR trial, an open-label, single-arm Phase II trial of Tumor Treating Fields together with pemetrexed and cisplatin or carboplatin in patients with newly diagnosed, unresectable malignant mesothelioma.
 
Smart bombs: The new weapon in the war on cancer
read story
The cancer world’s smart bomb comes in the form of an immunotoxin. Immunotoxins carry a payload of chemotherapy and attach to the cancerous cell, killing it when the time is right ...
 
Rosetta Genomics Announces Key Patent Allowances in U.S. and Europe
read story
Rosetta Genomics Ltd. , a leading developer and provider of microRNA-based molecular diagnostics, today announced that the Company received a Notice of Allowance from the United States Patent and Trademark Office for a patent claiming the use of miR-34a for the treatment of p53-associated cancers.
 
Aduro Biotech Collaborates with Leaders in Cancer Research on Investigator-Sponsored Phase 2 Trial Combining Aduro’s ...
read story
Aduro Biotech, Inc. today announced the initiation of an investigator-sponsored Phase 2 clinical trial of the company’s immuno-oncology product candidates GVAX Pancreas and CRS-207 in combination with Bristol-Myers Squibb’s Opdivo , a monoclonal antibody against programmed death-1 receptor .
 
NCCN Publishes New Patient-Friendly Treatment Guidelines for Acute Lymphoblastic Leukemia
read story
According to the NCCN Clinical Practice Guidelines in Oncology for Acute Lymphoblastic Leukemia , the treatment approach to ALL is one of the most complex and intensive programs in cancer therapy.The ...
 
Concordia Healthcare Corp. Provides Corporate Update
read story
Concordia Healthcare Corp. Provides Corporate Update